Interleukin 35 Protein (IL35) (Fc Tag)

Produktnummer ABIN7318088

Produktdetails

Target: Interleukin 35 (IL35)

Protein-Typ: Recombinant

Biologische Aktivität: Active

Spezies: Human

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses Interleukin 35 Protein ist gelabelt mit Fc Tag.

Verwendungszweck: Recombinant Human Interleukin-35/IL-35 Protein (Fc Tag)(Active)

Sequenz: Met 1-Lys 229

Produktmerkmale: A DNA sequence encoding the human IL35 complex composed of IL27B subunit (NP_005746.2) (Met 1-Lys 229) and the mature form of human IL12 p35 subunit (P29459) (Arg 23-Ser 219) linked by a polypeptide linker was fused with the Fc region of human IgG1 at the C-terminus.

Reinheit: > 85 % as determined by reducing SDS-PAGE.

Endotoxin-Niveau: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Measured by its ability to bind biotinylated human IL6RB-Fch in a functional ELISA.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.4

Lagerung: 4 °C,-20 °C,-80 °C

Informationen zur Lagerung: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Antigendetails

Target: Interleukin 35 (IL35)

Andere Bezeichnung: Interleukin-35/IL-35 (IL35 Produkte)

Hintergrund:

Background: The novel Ebi3-IL-12alpha heterodimeric cytokine has been designated interleukin-35 (IL-35); is a member IL12 family cytokine produced by regulatory T cells (Treg); but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of IL-12α (P35) and IL-27β chains; which are encoded by two separate genes called IL12A and EBI3 (Epstein-Barr-virus-induced gene 3) respectively. Ectopic expression of IL-35 confers regulatory activity on naive T cells; whereas recombinant IL-35 suppresses T-cell proliferation. It identify IL-35 as a novel inhibitory cytokine that may be specifically produced by T(reg) cells and is required for maximal suppressive activity. IL-35 has biological activity and able to expand CD4+CD25+ Treg cells; suppress the proliferation of CD4+CD25- effector cells and inhibit Th17 cell polarization. IL-35 has been shown to be constitutively expressed by regulatory T (Treg) cells CD4(+)CD25(+)Foxp3(+) and suggested to contribute to their suppressive activity. IL-35 is a crucial mediator which provokes CD4+CD25+ T cell proliferation and IL-10 generation; another well-known anti-inflammatory cytokine; along with TGFbeta cytokine. IL-35 is a cytokine can downregulate Th17 cell development and inhibit autoimmune inflammation. It inhibited the differentiation of Th17 cells in vitro. In vivo; IL-35 effectively attenuated established collagen-induced arthritis in mice; with concomitant suppression of IL-17 production but enhanced IFN-gamma synthesis. Thus; IL-35 is a novel anti-inflammatory cytokine suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell development.

Synonym: CLMF;IL-12A;IL-35;Interleukin-35;NFSK;NKSF1;P35

Molekulargewicht: 73.4 kDa